KATHRYN HEBERT: Open Payments
NPI 1124346218 · YOUNGSVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,292 in 80 payments from 17 companies in 2025. Trend: 2023 $1,703 · 2024 $1,037 · 2025 $1,292
Food & beverage: $1,292
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 13 | $196 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $165 |
| Alkermes, Inc. | 10 | $155 |
| ABBVIE INC. | 14 | $143 |
| Vanda Pharmaceuticals Inc. | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Janssen Pharmaceuticals, Inc | 2 | $49 |
| Supernus Pharmaceuticals, Inc. | 2 | $43 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Braeburn Inc. | 2 | $41 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, FANAPT, ABILIFY ASIMTUFII, REXULTI, UZEDY, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
